Development and evaluation of a medication counseling workshop for physicians: can we improve on ‘take two pills and call me in the morning’...

por Kripalani, Sunil, Osborn, Chandra Y., Vaccarino, Viola, Jacobson, Terry A.
Publicado 2011

Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia

por Rosenson, Robert S., Jacobson, Terry A., Preiss, David, Djedjos, C. Stephen, Dent, Ricardo, Bridges, Ian, Miller, Michael
Publicado 2016

Development and Content Validity of the Statin Experience Assessment Questionnaire (SEAQ)©

por Jacobson, Terry A., Edelman, Steven V., Galipeau, Nina, Shields, Alan L., Mallya, Usha G., Koren, Andrew, Davidson, Michael H.
Publicado 2016

The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): Revision for Clinical Use, Content Validation, and Inter-rater Reliability

por Rosenson, Robert S, Miller, Kate, Bayliss, Martha, Sanchez, Robert J, Baccara-Dinet, Marie T, Chibedi-De-Roche, Daniela, Taylor, Beth, Khan, Irfan, Manvelian, Garen, White, Michelle, Jacobson, Terry A.
Publicado 2017

Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE‐IT

por Selvaraj, Senthil, Bhatt, Deepak L., Steg, Ph. Gabriel, Miller, Michael, Brinton, Eliot A., Jacobson, Terry A., Juliano, Rebecca A., Jiao, Lixia, Tardif, Jean‐Claude, Ballantyne, Christie M.
Publicado 2022

Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking

por Miller, Michael, Bhatt, Deepak L, Steg, Ph Gabriel, Brinton, Eliot A, Jacobson, Terry A, Jiao, Lixia, Tardif, Jean-Claude, Ballantyne, Christie M, Budoff, Matthew, Mason, R Preston
Publicado 2022

Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn

por Miller, Michael, Bhatt, Deepak L, Brinton, Eliot A, Jacobson, Terry A, Steg, Philippe Gabriel, Pineda, Armando Lira, Ketchum, Steven B, Doyle, Ralph T, Tardif, Jean-Claude, Ballantyne, Christie M
Publicado 2023

The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint clinical perspective from the National Lipid Association and the Amer...

por Virani, Salim S., Aspry, Karen, Dixon, Dave L., Ferdinand, Keith C., Heidenreich, Paul A., Jackson, Elizabeth J., Jacobson, Terry A., McAlister, Janice L., Neff, David R., Gulati, Martha, Ballantyne, Christie M.
Publicado 2023

Rationale and design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

por Bhatt, Deepak L., Steg, Ph. Gabriel, Brinton, Eliot A., Jacobson, Terry A., Miller, Michael, Tardif, Jean‐Claude, Ketchum, Steven B., Doyle, Ralph T., Murphy, Sabina A., Soni, Paresh N., Braeckman, Rene A., Juliano, Rebecca A., Ballantyne, Christie M.
Publicado 2017

Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE‐IT

por Olshansky, Brian, Bhatt, Deepak L., Miller, Michael, Steg, Ph. Gabriel, Brinton, Eliot A., Jacobson, Terry A., Ketchum, Steven B., Doyle, Ralph T., Juliano, Rebecca A., Jiao, Lixia, Kowey, Peter R., Reiffel, James A., Tardif, Jean‐Claude, Ballantyne, Christie M., Chung, Mina K.
Publicado 2023

REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results

por Olshansky, Brian, Bhatt, Deepak L, Miller, Michael, Steg, Ph. Gabriel, Brinton, Eliot A, Jacobson, Terry A, Ketchum, Steven B, Doyle Jr, Ralph T, Juliano, Rebecca A, Jiao, Lixia, Granowitz, Craig, Tardif, Jean-Claude, Mehta, Cyrus, Mukherjee, Rajat, Ballantyne, Christie M, Chung, Mina K
Publicado 2020

Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL

por Majithia, Arjun, Bhatt, Deepak L., Friedman, Allon N., Miller, Michael, Steg, Ph. Gabriel, Brinton, Eliot A., Jacobson, Terry A., Ketchum, Steven B., Juliano, Rebecca A., Jiao, Lixia, Doyle, Ralph T., Granowitz, Craig, Budoff, Matthew, Preston Mason, R., Tardif, Jean-Claude, Boden, William E., Ballantyne, Christie M.
Publicado 2021

REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States

por Bhatt, Deepak L., Miller, Michael, Brinton, Eliot A., Jacobson, Terry A., Steg, Ph. Gabriel, Ketchum, Steven B., Doyle, Ralph T., Juliano, Rebecca A., Jiao, Lixia, Granowitz, Craig, Tardif, Jean-Claude, Olshansky, Brian, Chung, Mina K., Gibson, C. Michael, Giugliano, Robert P., Budoff, Matthew J., Ballantyne, Christie M.
Publicado 2020

Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses

por Peterson, Benjamin E., Bhatt, Deepak L., Steg, Ph. Gabriel, Miller, Michael, Brinton, Eliot A., Jacobson, Terry A., Ketchum, Steven B., Juliano, Rebecca A., Jiao, Lixia, Doyle, Ralph T., Granowitz, Craig, Gibson, C. Michael, Pinto, Duane, Giugliano, Robert P., Budoff, Matthew J., Tardif, Jean-Claude, Verma, Subodh, Ballantyne, Christie M.
Publicado 2020

Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment

por Weintraub, William S., Bhatt, Deepak L., Zhang, Zugui, Dolman, Sarahfaye, Boden, William E., Bress, Adam P., King, Jordan B., Bellows, Brandon K., Tajeu, Gabriel S., Derington, Catherine G., Johnson, Jonathan, Andrade, Katherine, Steg, P. Gabriel, Miller, Michael, Brinton, Eliot A., Jacobson, Terry A., Tardif, Jean-Claude, Ballantyne, Christie M., Kolm, Paul
Publicado 2022

Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE‐IT PCI

por Peterson, Benjamin E., Bhatt, Deepak L., Steg, Ph. Gabriel, Miller, Michael, Brinton, Eliot A., Jacobson, Terry A., Ketchum, Steven B., Juliano, Rebecca A., Jiao, Lixia, Doyle, Ralph T., Granowitz, Craig, Gibson, C. Michael, Pinto, Duane, Giugliano, Robert P., Budoff, Matthew J., Tardif, Jean‐Claude, Verma, Subodh, Ballantyne, Christie M.
Publicado 2022

Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

por Stroes, Erik S., Thompson, Paul D., Corsini, Alberto, Vladutiu, Georgirene D., Raal, Frederick J., Ray, Kausik K., Roden, Michael, Stein, Evan, Tokgözoğlu, Lale, Nordestgaard, Børge G., Bruckert, Eric, De Backer, Guy, Krauss, Ronald M., Laufs, Ulrich, Santos, Raul D., Hegele, Robert A., Hovingh, G. Kees, Leiter, Lawrence A., Mach, Francois, März, Winfried, Newman, Connie B., Wiklund, Olov, Jacobson, Terry A., Catapano, Alberico L., Chapman, M. John, Ginsberg, Henry N., Stroes, Erik, Thompson, Paul D., Corsini, Alberto, Vladutiu, Georgirene D., Raal, Frederick J., Ray, Kausik K., Roden, Michael, Stein, Evan, Tokgözoğlu, Lale, Nordestgaard, Børge G., Bruckert, Eric, Krauss, Ronald M., Laufs, Ulrich, Santos, Raul D., März, Winfried, Newman, Connie B., John Chapman, M., Ginsberg, Henry N., John Chapman, M., Ginsberg, Henry N., de Backer, Guy, Catapano, Alberico L., Hegele, Robert A., Kees Hovingh, G., Jacobson, Terry A., Leiter, Lawrence, Mach, Francois, Wiklund, Olov
Publicado 2015

Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract

por Mach, François, Ray, Kausik K, Wiklund, Olov, Corsini, Alberto, Catapano, Alberico L, Bruckert, Eric, De Backer, Guy, Hegele, Robert A, Hovingh, G Kees, Jacobson, Terry A, Krauss, Ronald M, Laufs, Ulrich, Leiter, Lawrence A, März, Winfried, Nordestgaard, Børge G, Raal, Frederick J, Roden, Michael, Santos, Raul D, Stein, Evan A, Stroes, Erik S, Thompson, Paul D, Tokgözoğlu, Lale, Vladutiu, Georgirene D, Gencer, Baris, Stock, Jane K, Ginsberg, Henry N, Chapman, M John
Publicado 2018